endpoints.news
is our new home on June 1. endpts.com will still work, but the front door is now
https://endpoints.news
Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Cell/Gene Tx channel feed
Takeda signs off on a $2B deal aimed at bypassing AAV roadblocks on the way to gene therapy 2.0
4 years ago
Deals
Lilly breaks the bank on the potential for RNA with $700M investment in Boston's Seaport
4 years ago
R&D
Homology joins BioMarin in halting gene therapy studies for rare metabolic disease
4 years ago
FDA starts probe into a clinical trial death as next-gen CAR-T researchers stop enrollment
4 years ago
FDA+
BioMarin gene therapy could be on hold 'for several quarters' after FDA mandates new preclinical tests
4 years ago
R&D
FDA+
Some genes are too large to fit into AAV vectors. UCB, Novartis back $57M idea to deliver them in parts instead
4 years ago
Financing
Startups
Biotech bear market be damned, CAR-T player Arcellx raises $123M IPO
4 years ago
Financing
Searching for CRISPR 2.0, Intellia spends $45M cash on an unknown Berkeley spinout
4 years ago
FDA slams clinical hold on LogicBio's gene editing drug after clotting cases in child patients
4 years ago
FDA+
Recently stung by AAV, Sarepta dives a little deeper into non-viral delivery with newest licensing pact
4 years ago
Deals
Oxford Biomedica enters the AAV manufacturing world, buying Homology's in-house business
4 years ago
Deals
Manufacturing
Can new manufacturing approaches finally make a decades-old cell therapy idea a reality?
4 years ago
Manufacturing
Well-connected, Gilead-backed biotech gets another stack of cash to pursue CAR-Ts for autoimmune disease
4 years ago
Financing
FDA slams door to pivotal trial for bubble boy disease gene therapy as Mustang Bio runs into another hold
4 years ago
'Altos was really a once-in-a-lifetime opportunity': Hal Barron reflects on his big move
4 years ago
Bioregnum
What kind of biotech startup wins a $3B syndicate, woos a gallery of marquee scientists and recruits GSK's Hal Barron as CEO in a stunner? Let Rick Klausner explain
4 years ago
Deals
UK upstart raises $100M in bid to digitize and standardize cell and gene therapy manufacturing
4 years ago
Manufacturing
FDA orders DMD trial halt, raising questions about a whole class of promising drugs
4 years ago
R&D
Three years, a clinical hold and a death later, Sarepta abandons partnered pivotal-stage gene therapy
4 years ago
Deals
Korean conglomerate SK takes out stake in cell and gene therapy CDMO with plans for a major hiring spree outside Philly
4 years ago
Manufacturing
Sarepta's second shot at showing its Duchenne gene therapy delivers positive data but underwhelms — shares tumble
4 years ago
R&D
Amicus gets hit with an 'unexpected' setback on a gene therapy tapped to lead $600M SPAC spinout
4 years ago
Bioregnum
Bristol Myers takes a swing at 'off-the-shelf' cell therapies in $150M cash licensing pact with Century
4 years ago
Deals
Continuing push beyond Covid-19 vaccines, Moderna partners with 'CAR-M' biotech on in vivo cancer cell therapies
4 years ago
Deals
First page
Previous page
31
32
33
34
35
36
37
Next page
Last page